Jazz Pharmaceuticals plc

NASDAQ:JAZZ

Biotechnology

Healthcare
$247.77 +0.02%

+$0.05 today

Market cap
$15.90B
Beta
0.33
P/E (TTM)
476.3
EPS (TTM)
$0.48
52W Low $105.00High $243.32

Volume 0.72M

Average 0.92M

JAZZ Long-term Debt

Borrowings due after more than one year.

Jazz Pharmaceuticals plcNASDAQ: JAZZ

Long-term Debt · Q3 FY2026 · quarter ended Sep 2026

Long-term debt falls 98.6% from a year ago

Long-term debt stood at $60.7M at the end of Q3 FY2026, down 98.6% from a year earlier and down 98.2% from the prior quarter. Over 3 fiscal years it compounded at -8.7% a year.

Context

  • Long-term debt amounted to 0.5% of total assets at the end of Q3 FY2026, down 37.6 pp from a year earlier.
  • Long-term debt increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether long-term debt keeps falling in the next quarterly balance sheet after a -98.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$60.7M-98.2% QoQ
Last fiscal yearDec 2025
$4.33B-28.8% YoY
Year agoSep 2025
$4.33B-98.6% since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-98.6%——
1 year-28.8%——
3-year CAGR-8.7%——
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
4.33B USD
Year-over-year change
-28.8%
4-year CAGR
-7.9%

Long-term Debt vs competitors

How JAZZ compares with its peers on the latest reported figures

  • JAZZ's Sep 2026 long-term debt of $60.7M is the 6th highest of the 9 companies compared; the peer median is $263.13M.
  • Its year-over-year change of -98.6% is the 3rd highest of 4, against a peer median of -12.6%.
  • Long-term debt amounts to 0.5% of total assets for JAZZ, versus a peer median of 12.1%.
JAZZ Competitors Peer median
Long-term Debt for JAZZ and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
GMABGenmab A/SJun 2026$4.84B ——38.7%
LGNDLigand Pharmaceuticals IncorporatedJun 2026$1.13B ——51.5%
TGTXTG Therapeutics, Inc.Sep 2026$745.63M +203.9%+52.6%46.8%
NBIXNeurocrine Biosciences, Inc.Sep 2026$392.3M ——7.0%
HRMYHarmony Biosciences Holdings, Inc.Jun 2026$133.96M -12.6%-7.9%9.8%
JAZZJazz Pharmaceuticals plcSep 2026$60.7M -98.6%-8.7%0.5%
MGNXMacroGenics, Inc.Mar 2026$31.3M ——14.4%
INCYIncyte CorporationJun 2026$0 ——0.0%
LEGNLegend Biotech CorporationSep 2026$0 -100.0%—0.0%
Peer median (excluding JAZZ) $263.13M-12.6%+22.3%12.1%

Competitors are the stored peer set for JAZZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents591.45M881.48M1.51B2.41B1.39B
Short-term Investments00120M580M1.05B
Net Receivables563.36M651.49M705.79M716.77M830.75M
Inventory1.07B714.06M597.04M480.45M416.96M
Other Current Assets252.39M267.19M320.81M261.54M323.95M
Total Current Assets2.61B2.61B3.44B4.63B4.17B
Property, Plant & Equipment (Net)343.42M301.38M234.99M227M258.74M
Goodwill1.83B1.69B1.75B1.72B1.83B
Intangible Assets7.15B5.79B5.42B4.76B4.43B
Long-term Investments5M5.5M04.33M4.3M
Tax Assets00477.83M560.25M869.13M
Other Non-current Assets358.95M435.14M73.94M119.64M102.28M
Total Non-current Assets9.69B8.23B7.96B7.38B7.49B
Total Assets12.3B10.84B11.39B12.01B11.66B
Account Payables100.3M90.76M102.75M77.87M122.06M
Short-term Debt31M31M604.95M31M1.03B
Tax Payables9.61M7.72M35.07M18.76M56.39M
Deferred Revenue2.09M463K000
Other Current Liabilities193.1M169.41M142.33M189.76M245.99M
Total Current Liabilities809.3M933.19M1.54B1.04B2.24B
Long-term Debt6.02B5.69B5.11B6.08B4.33B
Deferred Tax Liabilities1.3B944.34M847.71M676.74M594.47M
Deferred Revenue (Non-current)463K0000
Other Non-current Liabilities117M106.81M104.75M86.61M124.52M
Total Non-current Liabilities7.52B6.82B6.12B6.88B5.1B
Total Liabilities8.33B7.75B7.66B7.92B7.34B
Common Stock61K61K61K61K6K
Retained Earnings830.23M733.59M878.66M1.13B646.18M
Accumulated OCI(400.36M)(1.13B)(842.15M)(947.67M)(568.6M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity3.97B3.09B3.74B4.09B4.32B
Total Debt6.15B5.81B5.79B6.16B5.42B
Net Debt5.56B4.93B4.29B3.75B4.03B

Jazz Pharmaceuticals plc

NASDAQ:JAZZ

Intrinsic Alpha fair value

Locked

Current Price

$247.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.